Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: Compare alemtuzumab and basiliximab used for lung transplant in terms of rejection, CLAD, and mortality.
*Methods: A retrospective review of lung transplants performed between 2010 and 2016. Patients were excluded if younger than 18 years, had a previous lung transplant, received a multi-organ transplant, or died within 30 days of transplantation. Continuous and categorical variables were compared using T-test and Chi-squared, respectively.
*Results: 328 patients were reviewed; IPF (147) and COPD (114) were the most common indications for transplant. 304 were Caucasians and 179 were male. Median age was 61 in the alemtuzumab group and 56 in the basiliximab group. 241 patients received alemtuzumab and 87 received basiliximab. Recipients of basiliximab were significantly more likely to experience biopsy proven ACR (A2) rejection and BOS-III than those treated with alemtuzumab [table 1]. However, time to onset of CLAD (911.5 + 600 v. 1336 + 831 days; p<0.001) and time to death (1214 + 822 v. 818 + 596 days; p=0.011) were greater in the basiliximab group.
*Conclusions: More lung transplant recipients who received basiliximab experienced ACR compared with alemtuzumab, although there was a longer time to onset of CLAD and mortality.
To cite this abstract in AMA style:Mietz S, Roe D, Lushin E, Anderson E, Hage C. Comparison of Basiliximab and Alemtuzumab for Lung Transplant Induction [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-basiliximab-and-alemtuzumab-for-lung-transplant-induction/. Accessed March 6, 2021.
« Back to 2019 American Transplant Congress